Skip to main content
Premium Trial:

Request an Annual Quote

Multispan and Promega to Co-Develop Cell-Based GPCR Screening Tools

NEW YORK (GenomeWeb News) - Multispan and Promega said yesterday that they will co-develop assay tools for G-protein coupled receptor screening using Multispan’s GPCR cell lines and Promega’s bioluminescent technology.
 
The companies said that the initial tools to be developed under the agreement will use Promega’s cAMP-Glo Assay technology for signal quantification. The partners said they will develop additional tools for “cell-based assay detection,” but did not provide further details.
 
John Watson, marketing director for pharma and biotech at Promega, said that the protocols developed under the partnership should reduce assay-development times “from months to days.”
 
Financial details of the agreement were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.